Rigel Pharmaceuticals (RIGL) News Today → CEO of Biggest AI Chipmaker Just Dropped a Bombshell… (From Banyan Hill Publishing) (Ad) Free RIGL Stock Alerts $0.95 -0.03 (-3.06%) (As of 05/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13, 2024 | americanbankingnews.comFY2026 Earnings Estimate for Rigel Pharmaceuticals, Inc. Issued By HC Wainwright (NASDAQ:RIGL)May 11, 2024 | americanbankingnews.comFY2024 EPS Estimates for Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Increased by AnalystMay 11, 2024 | americanbankingnews.comStockNews.com Upgrades Rigel Pharmaceuticals (NASDAQ:RIGL) to BuyMay 10, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Analysts Are Pretty Bullish On The Stock After Recent ResultsMay 10, 2024 | marketbeat.comCantor Fitzgerald Comments on Rigel Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 earnings per share estimates for shares of Rigel Pharmaceuticals in a report issued on Wednesday, May 8th. Cantor Fitzgerald analyst K. Kluska now forecasts that the biotechnologyMay 10, 2024 | americanbankingnews.comRigel Pharmaceuticals (NASDAQ:RIGL) Rating Reiterated by HC WainwrightMay 8, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rigel’s Consistent Performance and Growth ProspectsMay 8, 2024 | finance.yahoo.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Receives Buy Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 price objective on shares of Rigel Pharmaceuticals in a report on Wednesday.May 8, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Issues Quarterly Earnings Results, Misses Estimates By $0.02 EPSRigel Pharmaceuticals (NASDAQ:RIGL - Get Free Report) announced its quarterly earnings data on Tuesday. The biotechnology company reported ($0.05) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.03) by ($0.02). During the same quarter last year, the company earned ($0.08) EPS.May 8, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Q1 2024 Earnings Call Transcript Highlights: Strategic Moves ...May 7, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q1 Loss decreases, but misses estimatesMay 7, 2024 | prnewswire.comRigel Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comRigel Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 1, 2024 | marketbeat.comRigel Pharmaceuticals (RIGL) to Release Earnings on TuesdayRigel Pharmaceuticals (NASDAQ:RIGL) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports.April 30, 2024 | prnewswire.comRigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdateApril 10, 2024 | prnewswire.comRigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)April 4, 2024 | prnewswire.comRigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaApril 3, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $2.89 Million Stake in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL)Assenagon Asset Management S.A. trimmed its holdings in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) by 28.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,991,398 sharesApril 1, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Sees Large Growth in Short InterestRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) was the recipient of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 4,940,000 shares, a growth of 32.1% from the February 29th total of 3,740,000 shares. Based on an average daily volume of 1,100,000 shares, the short-interest ratio is currently 4.5 days.March 27, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Raised to "Buy" at StockNews.comStockNews.com raised shares of Rigel Pharmaceuticals from a "hold" rating to a "buy" rating in a report on Wednesday.March 16, 2024 | finance.yahoo.comRIGL Apr 2024 3.000 callMarch 12, 2024 | finanznachrichten.deRigel Pharmaceuticals, Inc.: Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 12, 2024 | markets.businessinsider.comRigel Pharma Names Rojkjaer EVP, Chief Medical OfficerMarch 12, 2024 | prnewswire.comRigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical OfficerMarch 11, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Upgraded at StockNews.comStockNews.com raised Rigel Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Monday.March 11, 2024 | marketbeat.comFY2024 Earnings Forecast for Rigel Pharmaceuticals, Inc. Issued By Cantor Fitzgerald (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Equities researchers at Cantor Fitzgerald increased their FY2024 EPS estimates for Rigel Pharmaceuticals in a report issued on Wednesday, March 6th. Cantor Fitzgerald analyst K. Kluska now expects that the biotechnology company will post eMarch 8, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) to Post Q1 2024 Earnings of ($0.01) Per Share, B. Riley ForecastsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Stock analysts at B. Riley issued their Q1 2024 EPS estimates for shares of Rigel Pharmaceuticals in a report issued on Tuesday, March 5th. B. Riley analyst K. Patel forecasts that the biotechnology company will post earnings per share ofMarch 7, 2024 | finance.yahoo.comRigel Pharmaceuticals Inc (RIGL) Reports Growth in 2023 Sales, Despite Net Loss for the YearMarch 7, 2024 | insidermonkey.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | marketbeat.comCitigroup Raises Rigel Pharmaceuticals (NASDAQ:RIGL) Price Target to $4.00Citigroup boosted their target price on Rigel Pharmaceuticals from $3.00 to $4.00 and gave the stock a "buy" rating in a report on Thursday.March 7, 2024 | marketbeat.comB. Riley Weighs in on Rigel Pharmaceuticals, Inc.'s Q1 2025 Earnings (NASDAQ:RIGL)Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Free Report) - Research analysts at B. Riley issued their Q1 2025 earnings estimates for shares of Rigel Pharmaceuticals in a note issued to investors on Tuesday, March 5th. B. Riley analyst K. Patel anticipates that the biotechnology company will earn $March 6, 2024 | barrons.comRigel Pharmaceuticals Inc.March 6, 2024 | stockhouse.comRigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 6, 2024 | benzinga.comRigel Pharmaceuticals: Q4 Earnings InsightsMarch 6, 2024 | markets.businessinsider.comRigel Pharmaceuticals Inc. Q4 Earnings SummaryMarch 6, 2024 | msn.comRigel Pharmaceuticals GAAP EPS of $0.00 beats by $0.02, revenue of $35.8M beats by $2.39MMarch 6, 2024 | finance.yahoo.comOwning 47% shares,institutional owners seem interested in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL),March 6, 2024 | finance.yahoo.comQ4 2023 Rigel Pharmaceuticals Inc Earnings CallMarch 6, 2024 | marketbeat.comRigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Receives Consensus Rating of "Moderate Buy" from AnalystsRigel Pharmaceuticals, Inc. (NASDAQ:RIGL - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the four ratings firms that are presently covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and twoMarch 6, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Given New $3.00 Price Target at Cantor FitzgeraldCantor Fitzgerald increased their price target on Rigel Pharmaceuticals from $2.00 to $3.00 and gave the company a "neutral" rating in a research note on Wednesday.March 6, 2024 | marketbeat.comRigel Pharmaceuticals (NASDAQ:RIGL) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $15.00 price objective on shares of Rigel Pharmaceuticals in a research note on Wednesday.March 6, 2024 | gurufocus.comQ4 2023 Rigel Pharmaceuticals Inc Earnings Call TranscriptMarch 5, 2024 | investorplace.comRIGL Stock Earnings: Rigel Pharmaceuticals Beats Revenue for Q4 2023February 27, 2024 | prnewswire.comRigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business UpdateFebruary 26, 2024 | seekingalpha.comRigel Pharmaceuticals: Gavreto Deal Expands Growth ProspectsFebruary 23, 2024 | markets.businessinsider.comBuy Rating for Rigel: Strategic Acquisitions and Market Positioning Fuel Revenue Growth PotentialFebruary 23, 2024 | finance.yahoo.comRIGL Mar 2024 1.500 put Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth. One company holds a near-total monopoly on it. RIGL Media Mentions By Week RIGL Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RIGL News Sentiment▼0.510.50▲Average Medical News Sentiment RIGL News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RIGL Articles This Week▼72▲RIGL Articles Average Week Get Rigel Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Merrimack Pharmaceuticals News Emergent BioSolutions News Regulus Therapeutics News XOMA News Verastem News Vanda Pharmaceuticals News Lexicon Pharmaceuticals News Galectin Therapeutics News Omeros News Generation Bio News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RIGL) was last updated on 5/18/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingElon’s New Device is About to Shock the WorldInvestorPlaceMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceA once-in-a-century investment opportunityStansberry Research[URGENT] DO NOT Touch These AI Stocks!Weiss RatingsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rigel Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
